

Jean H Tayar

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6710998/jean-h-tayar-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

21
papers

655
citations

9
h-index

25
g-index

25
ext. papers

811
ext. citations

9.3
avg, IF

3.81
L-index

#	Paper	IF	Citations
21	Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma. <i>Journal of Immunotherapy and Precision Oncology</i> , 2022 , 5, 26-30	0.6	1
20	Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy.. <i>Nature Communications</i> , 2022 , 13, 1970	17.4	2
19	Case Discussion and Literature Review: Cancer Immunotherapy, Severe Immune-Related Adverse Events, Multi-Inflammatory Syndrome, and Severe Acute Respiratory Syndrome Coronavirus 2. <i>Frontiers in Oncology</i> , 2021 , 11, 625707	5.3	5
18	Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 70, 1939-1949	7.4	5
17	Systematic review of observational studies reporting antiphospholipid antibodies in patients with solid tumors. <i>Blood Advances</i> , 2020 , 4, 1746-1755	7.8	4
16	Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer. <i>Clinical Rheumatology</i> , 2020 , 39, 787-794	3.9	4
15	Overall survival in patients with rheumatoid arthritis and solid malignancies receiving biologic disease-modifying antirheumatic therapy. <i>Clinical Rheumatology</i> , 2020 , 39, 2943-2950	3.9	2
14	Myositis as an adverse event of immune checkpoint blockade for cancer therapy. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 48, 736-740	5.3	68
13	Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience 2019 , 7, 2		135
12	Coronary Lesions in Takayasu Arteritis With Chronic Myelogenous Leukemia - Intravascular Assessment With Optical Coherence Tomography and Fractional Flow Reserve. <i>Circulation Journal</i> , 2018 , 83, 245-246	2.9	4
11	Improvement of Smoking Abstinence Rates With Increased Varenicline Dosage: A Propensity Score-Matched Analysis. <i>Journal of Clinical Psychopharmacology</i> , 2018 , 38, 34-41	1.7	3
10	Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 2061-2064	2.4	107
9	Primary autoimmune myelofibrosis as etiology of pancytopenia mimicking myelodysplastic syndrome. <i>Leukemia and Lymphoma</i> , 2016 , 57, 731-4	1.9	3
8	Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: A case series. <i>Antiviral Research</i> , 2016 , 135, 91-96	10.8	15
7	Outcome of acute limb ischemia in cancer patients. <i>Vascular Medicine</i> , 2014 , 19, 112-117	3.3	12
6	Adalimumab: 8 years of experience in rheumatoid arthritis. <i>International Journal of Clinical Rheumatology</i> , 2013 , 8, 165-184	1.5	1
5	Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 308, 898-908	27.4	209

4	Febuxostat for treating chronic gout. <i>The Cochrane Library</i> , 2012 , 11, CD008653	5.2	18
3	Case 181: synovitis acne pustulosis hyperostosis osteitis (SAPHO) syndrome. <i>Radiology</i> , 2012 , 263, 613-720.5	7	
2	New understanding and approaches to treatment in rheumatoid arthritis. <i>British Medical Bulletin</i> , 2010 , 94, 201-14	5.4	15
1	Severe hyperosmolar metabolic acidosis due to a large dose of intravenous lorazepam. <i>New England Journal of Medicine</i> , 2002 , 346, 1253-4	59.2	34